A Phase 3 Study to Investigate the Safety and Efficacy of PA21, a Phosphate Binder, in Dialysis Patients
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
This is a Phase 3, randomised, active controlled, multicentre study to investigate the safety
and efficacy of PA21, a phosphate binder, for control of hyperphosphataemia in dialysis
patients. The primary objective is to establish the efficacy of PA21 for lowering phosphate
levels in these patients.